Harrow Health Inc Stock Price, News & Analysis

Harrow Health, Inc. (NASDAQ: HROW) announced participation in the H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021. CEO Mark Baum and CFO Andrew Boll will engage in a virtual presentation available on the company's investor relations site starting March 9, 2021, at 7:00 a.m. ET, archived for 90 days. The management team will also hold one-on-one meetings via H.C. Wainwright. Harrow Health specializes in ophthalmic healthcare and owns ImprimisRx, a leader in ophthalmology outsourcing and pharmaceutical compounding.

Harrow Health, Inc. (NASDAQ: HROW) announced it will release its fourth quarter and annual financial results for the year ending December 31, 2020, on March 8, 2021, after the market close. The financial results will be available on their website, and a conference call will occur at 4:45 p.m. ET to discuss the outcomes and present a business update. Harrow Health specializes in ophthalmic healthcare and owns ImprimisRx, a leading ophthalmology outsourcing business.

Melt Pharmaceuticals announced positive results from its Phase 1 MELT study, which evaluated the pharmacokinetic parameters of its novel midazolam and ketamine formulation. The study met its objectives, demonstrating good tolerance and relative bioavailability. The company plans to meet with the FDA to finalize its clinical protocol and commence a Phase 2 study in the third quarter of 2021, targeting cataract surgery patients. If approved, this non-opioid and IV-free option could significantly change pain management during surgeries.

Harrow Health (NASDAQ: HROW) announced a study published in the AANA Journal demonstrating the effectiveness of its MKO Melt® troche as a non-opioid alternative for IV sedation in cataract surgeries. The study involved 107 patients, comparing MKO Melt to traditional sedation methods. Findings indicated comparable comfort levels between both sedation methods, promoting MKO Melt for patients, especially those with needle-phobia. The MKO Melt has been used in over 250,000 cataract surgeries and is available for purchase through ImprimisRx.

Harrow Health (NASDAQ: HROW) will participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference from December 1-3, 2020. CEO Mark Baum and CFO Andrew Boll will present a corporate overview, with the management team available for one-on-one meetings. The pre-recorded presentation will be accessible to registered attendees from November 23 until December 3. Additionally, a replay of the conference presentation will be available for approximately 90 days on Harrow’s website.

Harrow Health (NASDAQ: HROW) reported exceptional financial results for Q3 2020, marking the best quarter in its history. Revenues increased month-over-month, achieving record gross margins and adjusted EBITDA. CEO Mark L. Baum expressed optimism about a continuous upward revenue trend heading into 2021, anticipating potential value inflection events. The company primarily focuses on ophthalmology through ImprimisRx and owns significant stakes in several pharmaceutical entities. A conference call discussing these results will be held on Nov. 9, 2020.

Harrow Health (NASDAQ: HROW) will announce its third quarter 2020 financial results after the market closes on November 9, 2020. A conference call will follow at 4:45 p.m. EST, providing an overview of the quarter and future outlook. Investors can access a press release and the company's Letter to Stockholders on its Investor Relations website. The call is intended for analysts to engage with the management team. Replay options for the call will be available until December 9, 2020, for dial-in listeners and until February 9, 2021, for webcast listeners.

Harrow Health (NASDAQ: HROW) will attend Lake Street’s 4th Annual Best Ideas Growth Conference on September 17, 2020, via a virtual platform. CEO Mark L. Baum and CFO Andrew Boll will be available for one-on-one meetings with investors throughout the day to discuss business updates. Interested parties should contact their Lake Street representative to arrange meetings or email conference@lakestreetcm.com for more information. Harrow Health owns a portfolio of healthcare businesses focused on patient-first solutions.

Harrow Health, Inc. (NASDAQ: HROW) announced its second quarter 2020 results, reporting a swift recovery post-COVID-19 impact. CEO Mark L. Baum highlighted record-high revenue days in Q3, attributed to effective product formulations and a new partnership with EyePoint Pharmaceuticals to market DEXYCU®. The company anticipates significant catalysts from Eton, Surface, and Melt in the coming months, bolstering optimism for shareholders.